The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 07, 2023
Filed:
Jul. 13, 2021
Applicant:
Biocryst Pharmaceuticals, Inc., Durham, NC (US);
Inventors:
Pravin L. Kotian, Hoover, AL (US);
Yarlagadda S. Babu, Birmingham, AL (US);
V. Satish Kumar, Birmingham, AL (US);
Weihe Zhang, Vestavia Hills, AL (US);
Lakshminarayana Vogeti, Lawrence, KS (US);
Assignee:
BioCryst Pharmaceuticals, Inc., Durham, NC (US);
Primary Examiner:
Int. Cl.
CPC ...
C07D 401/14 (2006.01); A61K 31/444 (2006.01); C07D 207/16 (2006.01); C07D 401/12 (2006.01); C07D 409/14 (2006.01); C07D 207/24 (2006.01); A61P 7/00 (2006.01); A61P 17/10 (2006.01); A61P 17/00 (2006.01);
U.S. Cl.
CPC ...
C07D 207/16 (2013.01); A61P 7/00 (2018.01); A61P 17/00 (2018.01); A61P 17/10 (2018.01); C07D 207/24 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 409/14 (2013.01);
Abstract
Disclosed are compounds of formula I, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.